drugset
drugset / Trial / NCT02086513

Phase I Trial of LDE225 for Steroid-refractory Chronic GVHD After Allogeneic HSCT

NCT02086513 ↗

Phase 1 Terminated 17 enrolled Massachusetts General Hospital Novartis · collab
NaSingle-groupOpen-labelTreatment

Summary

This is a phase I trial of LDE225 for the treatment of steroid-refractory chronic Graft Versus Host Disease (GVHD).

Timeline

Start
2014-04
Primary completion
2016-12
Completion
2016-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Sonidegib Small molecule 200 mg Oral
Subject Sonidegib Small molecule 400 mg Oral
Subject Sonidegib Small molecule 600 mg Oral
Subject Sonidegib Small molecule 800 mg Oral

Indications

chronic graft versus host disease